DOCSLIB.ORG

Herbal High Products

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Herbal High Products HERBAL HIGH PRODUCTS The following data has been obtained from the Therapeutic Goods Administration (TGA) Regulatory Compliance Unit and tested by the TGA Office of Laboratories and Scientific Services (OLSS). The products may no longer contain the offending substances, current testing may need to be considered. Prepared by: Senior Intelligence Officer Sasha Barclay TGA RCU (02) 62328067 27th of October 2009 IN CONFIDENCE 1 This document has been prepared by the Therapeutic Goods Administrations (TGA) Regulatory Compliance Unit for use by members of the Commonwealth of Australia- Department of Health and Ageing TGA. Unauthorised possession, use, viewing, duplication of this document and/or any of its contents, by any means whatsoever, is strictly prohibited unless prior approval is obtained from the Regulatory Compliance Unit TGA PRODUCT SUBSTANCES PACKAGING DETECTED Blessed Caffeine, phenylalanine, 2- phenylethylamine, ascorbic Sensory acid, geranamine and the Tablets kavalactones kavain and dihydrokavain were Company: detected in the sample. Nefarious, Date Tested: 21/09/09 Iced Caffeine 75.0mg/tab, Diamonds oxedrine (a.k.a. synephrine) 11.9 mg/tab, phenylalanine, Tablets ascorbic acid, and geranamine were detected in the samples. Hard Core Caffeine 74.8mg/tab, Tablets oxedrine (a.k.a. synephrine) 11.2 mg/tablet, phenylalanine, ascorbic acid, and geranamine were detected in the samples. IN CONFIDENCE 2 This document has been prepared by the Therapeutic Goods Administrations (TGA) Regulatory Compliance Unit for use by members of the Commonwealth of Australia- Department of Health and Ageing TGA. Unauthorised possession, use, viewing, duplication of this document and/or any of its contents, by any means whatsoever, is strictly prohibited unless prior approval is obtained from the Regulatory Compliance Unit TGA DIABLO Oxedrine (3.3 mg/tab), tablets geranamine, β-phenylethyl- amine, caffeine, Company: Light phenylalanine Years, New Zealand Date tested: 12/08/09 Hypnotic Oxedrine (30.1 mg/tab) S4 tablets level due to Daily advice, geranamine, phenylalanine, Company: Light glaucine, caffeine. Years, New Zealand Date tested: 12/08/09 HUMMER Oxedrine (8.3 mg/tab), geranamine, glaucine, tablets caffeine. Company: Light Years, New Zealand Date tested: 12/08/09 IN CONFIDENCE 3 This document has been prepared by the Therapeutic Goods Administrations (TGA) Regulatory Compliance Unit for use by members of the Commonwealth of Australia- Department of Health and Ageing TGA. Unauthorised possession, use, viewing, duplication of this document and/or any of its contents, by any means whatsoever, is strictly prohibited unless prior approval is obtained from the Regulatory Compliance Unit TGA Giggle Glaucine, caffeine and Tablets methylhexaneamine (aka Company: Light geranamine) were Years, New detected in the sample. Zealand. Date Tested: 12/10/09 Urban 4-methylmethcathinone Shamans 143mg/capsule Capsules Company: Party High Pills, Australia Date Tested: 12/10/09 Never Nap Caffeine was detected in Tablets samples of NeverNap Blue Dolphin Tablets Company: 171.9mg/tablet, Green Nevernap Industries, Stallions Tablets United Kingdom 161.7mg/tablet and Pink Bunnies Tablets 141mg/tablet. Date Tested: 26/08/09 IN CONFIDENCE 4 This document has been prepared by the Therapeutic Goods Administrations (TGA) Regulatory Compliance Unit for use by members of the Commonwealth of Australia- Department of Health and Ageing TGA. Unauthorised possession, use, viewing, duplication of this document and/or any of its contents, by any means whatsoever, is strictly prohibited unless prior approval is obtained from the Regulatory Compliance Unit TGA SPEED Oxedrine (9.3 mg/tab), RUSH, geranamine, caffeine. tablets Date Tested: 12/08/09 eBLAST, Oxedrine (12.6 mg/tab), tablets caffeine Date tested: 12/08/09 E=XTC, Oxedrine (12.6 mg/tab), tablets caffeine. Date tested: 12/08/09 IN CONFIDENCE 5 This document has been prepared by the Therapeutic Goods Administrations (TGA) Regulatory Compliance Unit for use by members of the Commonwealth of Australia- Department of Health and Ageing TGA. Unauthorised possession, use, viewing, duplication of this document and/or any of its contents, by any means whatsoever, is strictly prohibited unless prior approval is obtained from the Regulatory Compliance Unit TGA Speed Freak Ephedrine (4.8 mg/tab), capsules pseudoephedrine (2.6 mg/tab) kynurenic acid (+ Company: methoxylated analogue) Amsterdam 15.9mg High Co (AM- HI-CO) United Kingdom Date tested: 12/08/09 Rocket Fuel Ephedrine (4.7 mg/tab), capsules pseudoephedrine (2.4 mg/tab), kynurenic acid (+ Company: methoxylated analogue) Amsterdam 14.5mg High Co (AM- HI-CO) United Kingdom Date tested: 12/08/09 Vegas Caffeine, theophylline Nights (trace), ascorbic acid (Vitamin C), geranamine. capsules Company: Enjoi Supplements, New Zealand Date tested: 12/08/09 IN CONFIDENCE 6 This document has been prepared by the Therapeutic Goods Administrations (TGA) Regulatory Compliance Unit for use by members of the Commonwealth of Australia- Department of Health and Ageing TGA. Unauthorised possession, use, viewing, duplication of this document and/or any of its contents, by any means whatsoever, is strictly prohibited unless prior approval is obtained from the Regulatory Compliance Unit TGA Fast Layn Caffeine, theophylline capsules (trace), ascorbic acid (Vitamin C), geranamine. Company: Enjoi Supplements, New Zealand Date tested: 12/08/09 Trance Caffeine, ascorbic acid capsules (Vitamin C), geranamine. Company: Enjoi Supplements, New Zealand Date tested: 12/08/09 RED E Caffeine, theophylline capsules (trace), ascorbic acid (Vitamin C), geranamine. Company: Future Highs, New Zealand Date tested: 12/08/09 IN CONFIDENCE 7 This document has been prepared by the Therapeutic Goods Administrations (TGA) Regulatory Compliance Unit for use by members of the Commonwealth of Australia- Department of Health and Ageing TGA. Unauthorised possession, use, viewing, duplication of this document and/or any of its contents, by any means whatsoever, is strictly prohibited unless prior approval is obtained from the Regulatory Compliance Unit TGA Speed Caffeine, theophylline (trace), geranamine. capsules Company: Future Highs, New Zealand Date tested: 12/08/09 Euphori-e Caffeine (212.5 mg/cap), (U4-e) theobromine, catechins. Happy capsules Company: Happy Caps, The Netherlands Date tested: 30/06/08 Mister-e Caffeine (179.6 mg/cap), Happy theobromine, catechins, capsules capsaicin. Company: Happy Caps, The Netherlands Date tested: 30/06/08 IN CONFIDENCE 8 This document has been prepared by the Therapeutic Goods Administrations (TGA) Regulatory Compliance Unit for use by members of the Commonwealth of Australia- Department of Health and Ageing TGA. Unauthorised possession, use, viewing, duplication of this document and/or any of its contents, by any means whatsoever, is strictly prohibited unless prior approval is obtained from the Regulatory Compliance Unit TGA Space-e Caffeine (189.3 mg/cap), Happy theobromine, catechins, tryptophan (trace). capsules Company: Happy Caps, The Netherlands Date tested: 30/06/08 X-e Happy Caffeine (210.9 mg/cap), capsules theobromine, catechins. Company: Happy Caps, The Netherlands Date tested: 30/06/08 Sex-e Happy Levodopa (3 mg/cap), capsules caffeine (low level) & tryptophan (trace) Company: Happy Caps, The Netherlands Date tested: 30/06/08 IN CONFIDENCE 9 This document has been prepared by the Therapeutic Goods Administrations (TGA) Regulatory Compliance Unit for use by members of the Commonwealth of Australia- Department of Health and Ageing TGA. Unauthorised possession, use, viewing, duplication of this document and/or any of its contents, by any means whatsoever, is strictly prohibited unless prior approval is obtained from the Regulatory Compliance Unit TGA Lounge-e 5-hydroxytryptophan (74 Happy mg/cap), tryptophan (trace) capsules Company: Happy Caps, The Netherlands Date tested: 30/06/08 Groov-e Ephedrine (2.9 mg/cap), Happy Pseudoephedrine (1.4 mg/cap) capsules Caffeine (82.6 mg/cap), theobromine, catechins. Company: Happy Caps, The Netherlands Date tested: 30/06/08 Groove Glaucine and Geranamine Party pills were identified not quantified. They are not scheduled. Company: London Underground, New Zealand Date tested: 14/09/09 IN CONFIDENCE 10 This document has been prepared by the Therapeutic Goods Administrations (TGA) Regulatory Compliance Unit for use by members of the Commonwealth of Australia- Department of Health and Ageing TGA. Unauthorised possession, use, viewing, duplication of this document and/or any of its contents, by any means whatsoever, is strictly prohibited unless prior approval is obtained from the Regulatory Compliance Unit TGA Moove Party Caffeine 60.7mg/tablet, pills Glaucine and Geranamine. Company: London Underground Date tested: 14/09/09 Head Candy Diphenylprolinol tablets 48 mg/capsule. Glaucine 3.1 was tentatively identified. generation Diphenylprolinol and glaucine have been previously detected in Company: samples of London London Underground products Underground, (Neuroblast generation3.1 New Zealand. and Head Candy generation3.0) Date tested: 13/01/09 Neuro Blast tablets Diphenylprolinol generation3.1 77 mg/capsule. Company: London Underground, New Zealand. Date tested: 13/01/09 IN CONFIDENCE 11 This document has been prepared by the Therapeutic Goods Administrations (TGA) Regulatory Compliance Unit for use by members of the Commonwealth of Australia- Department of Health and Ageing TGA. Unauthorised possession, use, viewing, duplication of this
Load more

Recommended publications
  • Classical Recreational Drugs New Psychoactive Substances
    . Euro-DEN Plus: 2013-2017 . 23,947 presentations Classical Recreational Drugs and New Psychoactive Substances Professor Paul I Dargan Guy’s and St Thomas’ NHS Foundation Trust and King’s College London London, UK “Classical Drugs” Classification Stimulants Depressants MDMA (ecstasy) Opioids Amphetamine Benzodiazepines Cocaine GHB/GBL/1,4BD Hallucinogenics LSD Ketamine 1 Opioid Antagonist – Naloxone GHB and its Analogues GBL / 1,4BD . Competitive opioid antagonist – Onset 1-2 minutes, duration 30-90 minutes . Give in titrated 100 – 200 micrograms doses . Naloxone should be given IV – Can be given IM if no IV access . Aim to restore normal oxygenation/improve alertness . Infusion if long-acting preparation / features recur – Initial hourly dose of infusion is 2/3 of initial dose . What additional test is important in everyone with opioid toxicity? Paracetamol concentration . Ingestion of all 3 causes similar clinical features Effects of GHB / GBL Management of acute GHB/GBL toxicity 1-2mL . Mild-Moderate: – relaxation, appreciation for music & dancing, euphoria . Supportive care: ABC and monitoring – nausea, tremor, diarrhoea, agitation . Coma normally lasts 1-3 hours 3-4mL . Severe: . Airway reflexes generally well maintained – Increasing drowsiness …. coma, convulsions, respiratory depression, . Need for intubation: bradycardia – Not usually indicated if maintaining airway, no vomiting NB. Vomiting in 15-20%, convulsions in <10% . Think about dependence / risk of withdrawal in those with acute toxicity 3-6mL . Deaths: – Mostly pre-hospital, related to aspiration How many have seen a patient with this? 2 GHB Dependence/Withdrawal Acute Stimulant Toxicity . GHB: GABA-B agonist, also upregulates dopamine . Agitation and aggression, psychosis . Very frequent use: 1-2 hourly including overnight .
    [Show full text]
  • EUROPEAN COMMISSION Brussels, 11.7.2011 SEC(2011)
    EUROPEAN COMMISSION Brussels, 11.7.2011 SEC(2011) 912 final COMMISSION STAFF WORKING PAPER on the assessment of the functioning of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances Accompanying the document REPORT FROM THE COMMISSION on the assessment of the functioning of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances {COM(2011) 430 final} EN EN TABLE OF CONTENTS 1. Introduction...................................................................................................................3 2. Methodology.................................................................................................................4 3. Key findings from the 2002 evaluation of the Joint Action on synthetic drugs ...........5 4. Overview of notifications, types of substances and trends at EU level 2005-2010......7 5. Other EU legislation relevant for the regulation of new psychoactive substances.....12 6. Functioning of the Council Decision on new psychoactive substances .....................16 7. Findings of the survey among Member States............................................................17 7.1. Assessment of the Council Decision ..........................................................................17 7.2. Stages in the functioning of the Council Decision .....................................................18 7.3. National responses to new psychoactive substances ..................................................20
    [Show full text]
  • Pharmacology on Your Palms CLASSIFICATION of the DRUGS
    Pharmacology on your palms CLASSIFICATION OF THE DRUGS DRUGS FROM DRUGS AFFECTING THE ORGANS CHEMOTHERAPEUTIC DIFFERENT DRUGS AFFECTING THE NERVOUS SYSTEM AND TISSUES DRUGS PHARMACOLOGICAL GROUPS Drugs affecting peripheral Antitumor drugs Drugs affecting the cardiovascular Antimicrobial, antiviral, Drugs affecting the nervous system Antiallergic drugs system antiparasitic drugs central nervous system Drugs affecting the sensory Antidotes nerve endings Cardiac glycosides Antibiotics CNS DEPRESSANTS (AFFECTING THE Antihypertensive drugs Sulfonamides Analgesics (opioid, AFFERENT INNERVATION) Antianginal drugs Antituberculous drugs analgesics-antipyretics, Antiarrhythmic drugs Antihelminthic drugs NSAIDs) Local anaesthetics Antihyperlipidemic drugs Antifungal drugs Sedative and hypnotic Coating drugs Spasmolytics Antiviral drugs drugs Adsorbents Drugs affecting the excretory system Antimalarial drugs Tranquilizers Astringents Diuretics Antisyphilitic drugs Neuroleptics Expectorants Drugs affecting the hemopoietic system Antiseptics Anticonvulsants Irritant drugs Drugs affecting blood coagulation Disinfectants Antiparkinsonian drugs Drugs affecting peripheral Drugs affecting erythro- and leukopoiesis General anaesthetics neurotransmitter processes Drugs affecting the digestive system CNS STIMULANTS (AFFECTING THE Anorectic drugs Psychomotor stimulants EFFERENT PART OF THE Bitter stuffs. Drugs for replacement therapy Analeptics NERVOUS SYSTEM) Antiacid drugs Antidepressants Direct-acting-cholinomimetics Antiulcer drugs Nootropics (Cognitive
    [Show full text]
  • Glaucine Inhibits Breast Cancer Cell Migration and Invasion by Inhibiting MMP-9 Gene Expression Through the Suppression of NF-Jb Activation
    Mol Cell Biochem DOI 10.1007/s11010-015-2339-9 Glaucine inhibits breast cancer cell migration and invasion by inhibiting MMP-9 gene expression through the suppression of NF-jB activation Hyereen Kang • Sung-Wuk Jang • Jhang Ho Pak • Sungbo Shim Received: 14 November 2014 / Accepted: 30 January 2015 Ó The Author(s) 2015. This article is published with open access at Springerlink.com Abstract Matrix metalloproteinase-9 (MMP-9) plays a useful as a novel means of controlling breast cancer growth central role in the invasion and metastasis of various types and invasiveness. of cancer cells. Here, we demonstrate that glaucine, an al- kaloid isolated from the plant Corydalis turtschaninovii Keywords Invasion Á Migration Á MMPs Á Natural tuber (Papaveraceae), can inhibit the migration and invasion compound Á Breast cancer of human breast cancer cells. We further show that glaucine significantly blocks phorbol 12-myristate 13-acetate (PMA)-induced MMP-9 expression and activity in a dose- Introduction dependent manner. Results from reporter gene and elec- trophoretic mobility shift assays revealed that glaucine in- Metastasis is a defining characteristic of malignant cancer hibits MMP-9 expression by suppressing activation of the cells, and uncontrolled metastasis is the leading cause of death nuclear transcription factor nuclear factor-jB (NF-jB). in patients with cancer. Metastasis is a multi-step process in- Moreover, glaucine attenuates PMA-induced IjBa degra- volving degradation of the extracellular matrix (ECM), ad- dation and nuclear translocation of NF-jB. Finally, we also hesion of cancer cells to endothelial cells, extravasation found that glaucine inhibits invasion and MMP-9 expres- leading to infiltration of the underlying tissue, and metastatic sion in the highly metastatic MDA-MB-231 breast cancer foci formation [1, 2].
    [Show full text]
  • Appendix-2Final.Pdf 663.7 KB
    North West ‘Through the Gate Substance Misuse Services’ Drug Testing Project Appendix 2 – Analytical methodologies Overview Urine samples were analysed using three methodologies. The first methodology (General Screen) was designed to cover a wide range of analytes (drugs) and was used for all analytes other than the synthetic cannabinoid receptor agonists (SCRAs). The analyte coverage included a broad range of commonly prescribed drugs including over the counter medications, commonly misused drugs and metabolites of many of the compounds too. This approach provided a very powerful drug screening tool to investigate drug use/misuse before and whilst in prison. The second methodology (SCRA Screen) was specifically designed for SCRAs and targets only those compounds. This was a very sensitive methodology with a method capability of sub 100pg/ml for over 600 SCRAs and their metabolites. Both methodologies utilised full scan high resolution accurate mass LCMS technologies that allowed a non-targeted approach to data acquisition and the ability to retrospectively review data. The non-targeted approach to data acquisition effectively means that the analyte coverage of the data acquisition was unlimited. The only limiting factors were related to the chemical nature of the analyte being looked for. The analyte must extract in the sample preparation process; it must chromatograph and it must ionise under the conditions used by the mass spectrometer interface. The final limiting factor was presence in the data processing database. The subsequent study of negative MDT samples across the North West and London and the South East used a GCMS methodology for anabolic steroids in addition to the General and SCRA screens.
    [Show full text]
  • Allosteric Modulators of G Protein-Coupled Dopamine and Serotonin Receptors: a New Class of Atypical Antipsychotics
    pharmaceuticals Review Allosteric Modulators of G Protein-Coupled Dopamine and Serotonin Receptors: A New Class of Atypical Antipsychotics Irene Fasciani 1, Francesco Petragnano 1, Gabriella Aloisi 1, Francesco Marampon 2, Marco Carli 3 , Marco Scarselli 3, Roberto Maggio 1,* and Mario Rossi 4 1 Department of Biotechnological and Applied Clinical Sciences, University of l’Aquila, 67100 L’Aquila, Italy; [email protected] (I.F.); [email protected] (F.P.); [email protected] (G.A.) 2 Department of Radiotherapy, “Sapienza” University of Rome, Policlinico Umberto I, 00161 Rome, Italy; [email protected] 3 Department of Translational Research and New Technology in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy; [email protected] (M.C.); [email protected] (M.S.) 4 Institute of Molecular Cell and Systems Biology, University of Glasgow, Glasgow G12 8QQ, UK; [email protected] * Correspondence: [email protected] Received: 26 September 2020; Accepted: 11 November 2020; Published: 14 November 2020 Abstract: Schizophrenia was first described by Emil Krapelin in the 19th century as one of the major mental illnesses causing disability worldwide. Since the introduction of chlorpromazine in 1952, strategies aimed at modifying the activity of dopamine receptors have played a major role for the treatment of schizophrenia. The introduction of atypical antipsychotics with clozapine broadened the range of potential targets for the treatment of this psychiatric disease, as they also modify the activity of the serotoninergic receptors. Interestingly, all marketed drugs for schizophrenia bind to the orthosteric binding pocket of the receptor as competitive antagonists or partial agonists.
    [Show full text]
  • Mushroom Magick Pdf, Epub, Ebook
    MUSHROOM MAGICK PDF, EPUB, EBOOK Arik Roper,Erik Davis,Daniel Pinchbeck | 144 pages | 24 Apr 2009 | Abrams | 9780810996311 | English | New York, United States Mushroom Magick PDF Book So he took some of them, and, squeezing the juice into a vessel, drank it. Aztecs and Mazatecs referred to psilocybin mushrooms as genius mushrooms, divinatory mushrooms, and wondrous mushrooms, when translated into English. It is widely believed that his second wife, Aggripinna, who wanted her son Nero to have the throne, deliberately poisoned her husband. In Chinese Mythology, mushrooms were one of the sacred foods eaten by the Immortals; they induced bodily lightness. Magic mushrooms are often prepared by drying and are eaten by being mixed into food or drinks, although some people eat freshly picked magic mushrooms. Anthoney O'callaghan on March 17, am. Here is a good story told by Paul Stamets that explains how he took 25 grams when he had a severe stuttering problem and the next day he was completely cured:. Notably, one loses time in the world of faerie, as one does under the influence of the mushroom. Psychedelics are very intoxicating substances, and their side effects can be challenging to manage even in the relatively safe framework of a research setting, Johnson said. Glaucine Isoaminile Noscapine Pukateine. Keep downloading, keep listening! If you do, it is very important to ensure that your set and setting are very supportive and safe. Arguments for and against drug prohibition Capital punishment for drug trafficking Cognitive liberty Designer drug Drug court Drug possession Drug test Narc Politics of drug abuse War on drugs Mexican drug war Plan Colombia Philippine drug war Zero tolerance.
    [Show full text]
  • Pharmacology
    STATE ESTABLISHMENT «DNIPROPETROVSK MEDICAL ACADEMY OF HEALTH MINISTRY OF UKRAINE» V.I. MAMCHUR, V.I. OPRYSHKO, А.А. NEFEDOV, A.E. LIEVYKH, E.V.KHOMIAK PHARMACOLOGY WORKBOOK FOR PRACTICAL CLASSES FOR FOREIGN STUDENTS STOMATOLOGY DEPARTMENT DNEPROPETROVSK - 2016 2 UDC: 378.180.6:61:615(075.5) Pharmacology. Workbook for practical classes for foreign stomatology students / V.Y. Mamchur, V.I. Opryshko, A.A. Nefedov. - Dnepropetrovsk, 2016. – 186 p. Reviewed by: N.I. Voloshchuk - MD, Professor of Pharmacology "Vinnitsa N.I. Pirogov National Medical University.‖ L.V. Savchenkova – Doctor of Medicine, Professor, Head of the Department of Clinical Pharmacology, State Establishment ―Lugansk state medical university‖ E.A. Podpletnyaya – Doctor of Pharmacy, Professor, Head of the Department of General and Clinical Pharmacy, State Establishment ―Dnipropetrovsk medical academy of Health Ministry of Ukraine‖ Approved and recommended for publication by the CMC of State Establishment ―Dnipropetrovsk medical academy of Health Ministry of Ukraine‖ (protocol №3 from 25.12.2012). The educational tutorial contains materials for practical classes and final module control on Pharmacology. The tutorial was prepared to improve self-learning of Pharmacology and optimization of practical classes. It contains questions for self-study for practical classes and final module control, prescription tasks, pharmacological terms that students must know in a particular topic, medical forms of main drugs, multiple choice questions (tests) for self- control, basic and additional references. This tutorial is also a student workbook that provides the entire scope of student’s work during Pharmacology course according to the credit-modular system. The tutorial was drawn up in accordance with the working program on Pharmacology approved by CMC of SE ―Dnipropetrovsk medical academy of Health Ministry of Ukraine‖ on the basis of the standard program on Pharmacology for stomatology students of III - IV levels of accreditation in the specialties Stomatology – 7.110105, Kiev 2011.
    [Show full text]
  • Download File
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable (1.1.2c) Psychomotor relevant performance: 1. After single dose administration of opioids, narcoanalgesics and hallucinogens to drug naïve subjects 2. In patients treated chronically with morphine or methadone / buprenorphine Due date of deliverable: (14.08.2010) Actual submission date: (02.03.2011) Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: Norwegian Institute of Public Health Revision 3.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public X PP Restricted to other programme participants (including the Commission Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DELIVERABLE 1.1.2C – NORWEGIAN INSTITUTE OF PUBLIC HEALTH PAGE 2 Psychomotor relevant performance: 1. After single dose administration of opioids, narcoanalgesics and hallucinogens to drug naïve subjects 2. In patients treated chronically with morphine or methadone/buprenorphine Maren Cecilie Strand1, Bente Fjeld1, Marianne Arnestad1, Jørg Mørland1 1Norwegian Institute of Public Health, Division of Forensic Toxicology and Drug Abuse, PO Box 4404
    [Show full text]
  • Glaucine-Containing Plants of the Genus Glaucium
    GLAUCINE- CONTAINING PLANTS OF THE GENUS Glaucium L. D. Yakhontova, O. N. Tolkaehev, UDC 547- 94 and D. A. Pakaln The alkaloid glaucine, which is used as an antitussive agent and is obtained from plants of the genus Glaucium, family Papaveraceae, has previously been detected only in G. flavurap G. serpieri, and G. ele- gans [1-3]. We have found that glaucine is also present in the epigeal part ofG. grandiflor~]m~ the alkaloid composition of which has not previously been studied. The herbage and roots of this plant collected in Armenia in the environs of the village of Khachik in 1971-1972 in the flowering period were investigated. From the epigeal part 0.6% of combined alkaloids was obtained by the dichloroethane method, and the separation of these on alumina gave glaucine, O-meth- ylatheroline, glauvine, protopine, isoboldine, and a base with mp 191-192°C (from ethanol), glaucine making up about 50% of the combined weight of the alkaloids. The first five alkaloids were identified by direct com- parison with authentic samples. The alkaloid with mp 191-192°C had the composition C20H~sNO4, [~]~+ 40 ° (c 1; chloroform). UV spectrum: ~'max 220, 280, 305 nm (log 8 4.58, 4.14, 4.18). IR spectrum--3250- 3350 cm-1. The NMR spectrum of the base (HA-100, CDC13, I-IMDS) showed a three-proton singlet of N- CH3 at 2.47 ppm, three three-proton singlets of OCH3 groups at 3.78, 3.82, and 3.83 ppm, three singlets of aromatic protons (6.44 ppm- C3H; 6.69 ppm- CsH; 7.98 ppm- CilH), a diffuse signal of a hydroxyl proton at 6.37 ppm, and also multiplets of CH2 groups in the 2.4-2.7 and 2.8-3.1 ppm regions.
    [Show full text]
  • Psychoactive Natural Products: Overview of Recent Developments
    12 Ann Ist Super Sanità 2014 | Vol. 50, No. 1: 12-27 DOI: 10.4415/ANN_14_01_04 Psychoactive natural products: overview of recent developments István Ujváry REVIEWS iKem BT, Budapest, Hungary AND Abstract Natural psychoactive substances have fascinated the curious mind of shamans, artists, Key words ARTICLES scholars and laymen since antiquity. During the twentieth century, the chemical com- • ethnopharmacology position of the most important psychoactive drugs, that is opium, cannabis, coca and • mode of action “magic mushrooms”, has been fully elucidated. The mode of action of the principal in- • natural products gredients has also been deciphered at the molecular level. In the past two decades, the • psychopharmacology RIGINAL use of herbal drugs, such as kava, kratom and Salvia divinorum, began to spread beyond • toxicology O their traditional geographical and cultural boundaries. The aim of the present paper is to briefly summarize recent findings on the psychopharmacology of the most prominent psychoactive natural products. Current knowledge on a few lesser-known drugs, includ- ing bufotenine, glaucine, kava, betel, pituri, lettuce opium and kanna is also reviewed. In addition, selected cases of alleged natural (or semi-natural) products are also mentioned. O, mickle is the powerful grace that lies In herbs, plants, stones, and their true qualities William Shakespeare (Romeo and Juliet) INTRODUCTION Historical background of psychoactive natural During the past 200 years, there has been major pro- products research gress in our understanding of the composition and ef- The biochemical machinery of an organism generates fects of many psychoactive natural products, particular- many structurally related chemicals (Nature’s “combinato- ly those that have therapeutic uses.
    [Show full text]
  • Interactions of a Medicinal Climber Tinospora Cordifolia with Supportive
    www.nature.com/scientificreports OPEN Interactions of a medicinal climber Tinospora cordifolia with supportive interspecifc plants trigger the Received: 22 March 2019 Accepted: 17 September 2019 modulation in its secondary Published: xx xx xxxx metabolic profles Bhawana Sharma, Aarti Yadav & Rajesh Dabur Tinospora cordifolia (TC) is scientifcally proven immunomodulatory drug being used for centuries. Ancient literature reported that inter-specifc interactions change medicinal properties of TC. Thus, the current study is aimed to understand the infuence of interspecifc biotic interactions on chemo-profles of TC. To explore it, TC samples collected from six co-occurring plants, i.e. Azarditchita indica, Acacia nilotica, Albezia lebbeck, Ficus benghalensis, Tamarandus indica and Acacia leucophloea were analyzed by HPLC-ESI-QTOF-MS. Mass data were subjected to multivariate analysis. Support vector machines (SVMs) was found to be best classifer (r2 < 0.93). Data analysis showed the specifc compounds in all TC due to inter-specifc interactions. Data were further analyzed with SNK post-hoc test followed by permutative (n = 50) Bonferroni FDR multiple testing correction. The compound without any missing values reduced the number of variables to 133 (p < 0.01). Statistical analysis revealed that TC having interactions with A.lebbeck and A. nilotica formed the most distant groups. However, TC co-occurred with A. indica showed the highest number of up-regulated metabolites, including jatrorrhizine, chrysin, peonidin, 6-methylcoumarin and some terpenoids. Some metabolites, including jatrorrhizine and magnoforine were quantifed to confrm the accuracy of qualitative analysis. Results demonstrated the infuence of inter-specifc biotic interactions on TC chemo-profles, hence its medicinal properties.
    [Show full text]